Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483863 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL1329382 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL26160440 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| Oxalic Acid SCHEMBL23880753 | 0.96 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| Benzene SCHEMBL28127008 | 0.96 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL23880754 | 0.94 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL9067705 | 0.92 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL3268775 | 0.92 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL30415495 | 0.92 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL2476602 | 0.92 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329827-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | Alphathera AG (CH) | 2024-03-06 | — | — | EP | claimed |
| WO-2022231424-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | ALPHATHERA AG (CH) | 2022-11-03 | — | — | WO | claimed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4676598-A1 | PEPTIDOGLYCAN HYDROLASES WITH BACTERICIDAL ACTIVITY | BioNTech SE (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-2434421-A2 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20100280803-A1 | Compositions and Methods for Modeling Saccharomyces cerevisiae Metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-11-04 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-7751981-B2 | Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | ALDH1A1 2671/4885LMNA 4278/4885MAPT 1236/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | ALDH1A1 3429/4885LMNA 2873/4885MAPT 3584/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | ALDH1A1 4304/4885LMNA 4379/4885MAPT 3005/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | ALDH1A1 4504/4885LMNA 4070/4885MAPT 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.